Business
KALY Targets First $1 Million In Cannabis Extract Sales For Consumer Market
KALY Targets First $1 Million In Cannabis Extract Sales For Consumer Market.
About this update from Kali Inc
[{"type":"text","content":"\nDALLAS, April 17, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today published a presentation elaborating on the company’s overall strategy to discover, develop and commercialize novel therapeutics from its proprietary cannabinoid product platform.  In addition to detailing its cannabis extracts biopharmaceutical strategy, the presentation includes details on KALY’s parallel consumer market strategy separate from the pharmaceutical industry.  Management is targeting $1 million in sales outside the pharmaceutical space in 2019.  See the full presentation published today below.\n Patented Cannabis Extracts Targeting $170 In Million Pharmaceutical Treatments In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB).  NCMB is biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas.  In four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process.  The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity.  KALY, through its subsidiary, NCMB has a deep pipeline of additional cannabinoid product candidates including four distinct compounds.  KALY has completed the first stage of clinical development and testing for a Chronic Obstructive Pulmonary Disease (COPD) therapy and is currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy. $170 Million Cannabis Therapeutics Market Opportunity Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025;  Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026; Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024, and  Epilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022. Cannabis Research Methodology KALY, thr...